All In MedTech

FDA Clearance Tracker · P080011-S191

Sofmed® breathables™ XW NEXT

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 5, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Dec 5, 2025

Approved

Time to decision

140 days

Received Jul 18, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P080011-S191
Device name
Sofmed® breathables™ XW NEXT
Applicant location
San Ramon, CA
Received
Jul 18, 2025
Decided
Dec 5, 2025
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P080011

Device type

Device class
Class III
Regulation
21 CFR 886.5925
Specialty
Ophthalmology

Every decision under product code LPM

FDA's approval statement

As written in FDA's record.

re-branding of the Biofinity® (comfilcon A) Soft Contact Lenses for Extended Wear to the new private label trade name “Sofmed® breathables™ XW NEXT.

Source documents

Other decisions for CooperVision, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.